Dr. Martens plc (DOCS.L)
| Previous Close | 85.40 |
| Open | 83.20 |
| Bid | 80.00 x N/A |
| Ask | 87.50 x N/A |
| Day's Range | 83.00 - 87.30 |
| 52 Week Range | 62.00 - 168.70 |
| Volume | |
| Avg. Volume | 2,193,053 |
| Market Cap | 828.708M |
| Beta (5Y Monthly) | 0.01 |
| PE Ratio (TTM) | 8.61 |
| EPS (TTM) | 0.10 |
| Earnings Date | May 30, 2024 |
| Forward Dividend & Yield | 0.06 (6.84%) |
| Ex-Dividend Date | Jan 04, 2024 |
| 1y Target Est | 75.77 |
Yahoo Finance UKStocks to watch next week: Salesforce, Pets at Home, Abercrombie & Fitch and Dr Martens
Earnings preview of key companies reporting this week and what to look out for.
ReutersMarathon Partners urges Dr Martens to buy back stock, detail expense cuts
BOSTON (Reuters) -Investment firm Marathon Partners Equity Management is turning up the heat on Dr Martens by urging the British boot maker to detail planned expense cuts and to buy back stock, people familiar with the matter told Reuters. The increased pressure comes roughly two months after Marathon Partners' managing member Mario Cibelli suggested Dr Martens launch a strategic review that could lead to its sale, arguing it was the best way forward for the company, whose chunky lace-up boots have been a fashion statement since the 1960s. Cibelli has told executives it would be sensible for Dr Martens to lay out specific plans when it announces earnings on May 30, which are expected to be in line with previously issued guidance, the sources said.
FortuneGen Z favorite Dr. Martens is struggling as its CEO steps down—and it might be because their shoes last too long
Famously made to last, the durability that led to its popularity may be the very thing keeping it from astronomic growth.
